Lundbeckfonden BioCapital

🏷️ vc
Visit Website ↗
Investment Thesis

SNIPR Biome leverages CRISPR-Cas technology to develop microbial medicines for precision killing of bacteria and gene modification, addressing critical infectious diseases like antibiotic-resistant infections in cystic fibrosis and hematologic cancers. The company focuses on selective, ultra-rapid bacterial eradication while preserving the patient’s microbiome, with a pipeline targeting pathogens of high importance, including Pseudomonas aeruginosa and antibiotic-resistant bacteria.

Stage Focus
Clinical-Stage

Preferred startup development maturity for initial funding deployment.

Sectors & Themes

CRISPR-based microbial interventions, precision killing of bacteria, and gene modification for therapeutic applications targeting antimicrobial resistance and infectious diseases

Core thematic spaces, technologies, and target market segments of interest.

Check Size Range
N/A - €35,000,000

Standard financial allocation per investment round.

Outreach & Dossier Intelligence

Direct Verification Contact Email Pattern

[email protected] | [email protected]

Thesis Dossier Analysis Scorecard

Our agent analyzer scanned portfolio holdings and verified absolute match parameters...

Unlock Verified Partner Contacts

Find verified email templates, direct outreach copy created by AI, and calculate exact thesis match scores with 1-click.

Create Free Account to Unlock

Takes less than 30 seconds · No card required

Investment Team (7)